Sanofi Pasteur, the vaccines division of French drug major Sanofi-Aventis, says that its seasonal influenza vaccine Intanza/IDflu has been approved in Europe.
According to Sanofi, which is the world's third-largest drugmaker by sales, the convenience and the ease of administration of the product should help improve the coverage rate in Europe.
The agent will be used for the prevention of seasonal influenza in both the adult (aged 18 and over) and elderly (aged 60 and over) populations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze